MONDAY, Dec. 16, 2024 (HealthDay News) -- The established hormone therapy drug tamoxifen can significantly decrease the risk of cancer recurring in women with an early, low-risk form of breast ...

aThe Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA bThe Division of Hematology/Oncology, Northwestern University, Chicago, IL, USA Tamoxifen is the most widely ...

Scientists have developed a single-dose treatment for breast cancer that eliminates small tumors and significantly shrinks ...

However, few experimental or clinical studies address the combined effects of hormone and radiation therapy. Preclinical models have shown changes in tumour cell kinetics with the addition of ...

breast cancer develop resistance to hormone treatment, and a potential new approach to overcome the problem. Around 80% of breast cancers are ER+ and are treated with anti-oestrogen therapies such as ...

following tamoxifen for 2–3 years (early 'switch' treatment) or 5 years (extended adjuvant treatment). Reducing recurrence risk is a primary goal of adjuvant hormonal therapy. There is an early ...

Background: Tamoxifen (Tam) is used for the treatment and prevention of estrogen-receptor-positive human breast and other cancers. Its use in ovarian cancer has not been well studied. Method ...

Click now to see all the available groups. The hormone therapy tamoxifen can keep cancer from recurring in women with DCIS Tamoxifen following lumpectomy reduced risk of recurrence 44% to 51% ...

Women with oestrogen-sensitive breast cancer now receive anti-hormonal therapy. Researchers have ... with oestrogen-suppressing drugs, often tamoxifen. However, anti-hormonal treatment reduces ...